Use of Myoinositol in Polycystic Ovary Syndrome

    September 2025 in “ Obstetrics and gynecology. ”
    Shadab Salehpour, Sedighe Hosseini, Zahra Zarisfi
    From the encyclopedia
    Metformin →

    diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties

    Folic acid →
    Studysummary This review examines the pathophysiology of PCOS and reports that myoinositol may improve menstrual regularity, insulin sensitivity, and reproductive outcomes, with comparable efficacy to metformin and often better tolerability.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    Myoinositol (MI) is a promising treatment for managing Polycystic Ovary Syndrome (PCOS), showing comparable efficacy to metformin with fewer side effects. Studies and meta-analyses involving thousands of participants have demonstrated MI's benefits in improving insulin sensitivity, reducing androgen levels, and enhancing ovulation and menstrual regularity. MI supplementation (2-4 g/day) lowers fasting insulin levels, improves hormonal balance, and increases ovulation rates, enhancing fertility outcomes. It also supports mental health by modulating serotonin pathways. The recommended dosage is 4 grams per day, typically over 3 to 6 months, and is generally safe with mild gastrointestinal side effects. Combination therapies with D-chiro-inositol, folic acid, and other supplements may offer additional benefits. While MI is increasingly recognized in clinical guidelines, further high-quality research is needed to optimize individualized patient care.
    Discuss this study in the Community →

    Research cited in this study

    13 / 13 results